Genfit SA (GNFT) AI Stock Analysis

• Market Cap: $206.09M
• Dividend Yield: N/A
• Average Volume (3M): 8.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: -44.94%
• EPS Growth: -274.42%
• Country: US
• Employees: 180
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 50,002,895
• 10 Day Avg. Volume: 7,898
• 30 Day Avg. Volume: 8,053
• PEG Ratio: -1.14
• Price to Book (P/B): 2.61
• Price to Sales (P/S): 2.69
• P/FCF Ratio: 12.69
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 3.32
• Enterprise Value/Gross Profit: 3.29
• Enterprise Value/Ebitda: 28.52
• 1Y Price Target: $7.50
• Price Target Upside: 89.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $4.00 ▲(1.01% Upside)

Genfit SA's overall stock score is primarily influenced by its financial performance, which shows a positive recovery trajectory. However, technical indicators suggest bearish momentum, and the valuation is weak due to the negative P/E ratio and lack of dividend yield. These factors collectively result in a moderate overall score.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful product commercialization and market acceptance, supporting long-term financial stability.

Cash Generation

Improved cash generation enhances financial flexibility, allowing for reinvestment in R&D and strategic initiatives, bolstering growth prospects.

Strategic Focus

Focusing resources on core operations and primary markets can lead to better operational efficiency and sustained competitive advantage.

Negative Factors

Operating Margins

Low operating margins suggest inefficiencies that could hinder profitability and limit the ability to invest in growth opportunities.

Program Discontinuation

Halting a key program may impact future revenue streams and reflects challenges in clinical development, affecting long-term growth.

Revenue Decline

A significant decline in revenue growth could indicate market challenges or product issues, impacting financial health and investor confidence.

Genfit SA Business Overview & Revenue Model

Company Description

Genfit SA (GNFT) is a biopharmaceutical company focused on developing innovative therapeutic and diagnostic solutions for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH) and other liver-related conditions. The company operates primarily in the healthcare sector, emphasizing research and development to advance its portfolio of drug candidates and diagnostic tools aimed at improving patient outcomes in liver diseases and metabolic disorders.

How the Company Makes Money

Genfit generates revenue through multiple streams, primarily from the development and commercialization of its pharmaceutical products. The company focuses on advancing its lead drug candidates through clinical trials, aiming for regulatory approvals that can lead to market entry. In addition to potential sales from its proprietary drugs, Genfit may also derive revenue from partnerships and collaborations with other pharmaceutical companies, which can include upfront payments, milestone payments, and royalties on future sales. Furthermore, Genfit has a diagnostic business segment, where it offers tests that assess liver health, contributing to its overall revenue. Strategic alliances with research institutions and industry partners enhance its capabilities and support its financial growth.

Genfit SA Financial Statement Overview

Summary

Genfit SA has shown a robust recovery in 2024 with significant revenue growth and a return to profitability. The high gross profit margin and improved cash flow generation are notable strengths. However, low operating margins and moderate leverage ratios indicate areas needing strategic improvement.

Income Statement

Genfit SA's income statement shows a significant recovery in 2024, with total revenue increasing by 134.5% from 2023. The gross profit margin is strong at 99.55% due to high gross profits relative to revenue. The company has turned around its net profitability with a net profit margin of 2.25% in 2024 compared to losses in previous years. However, the EBIT and EBITDA margins remain relatively low at 4.90% and 12.41%, indicating room for improvement in operating efficiency.

Balance Sheet

Genfit SA's balance sheet reflects moderate stability with a debt-to-equity ratio of 0.90, suggesting a balanced use of debt and equity. The return on equity (ROE) is modest at 2.18%, reflecting limited profitability relative to equity. The equity ratio of 45.72% indicates a fair portion of assets are funded by equity, providing a stable foundation, yet there's a need to enhance asset efficiency and leverage.

Cash Flow

The cash flow statement shows a significant improvement in 2024 with a positive free cash flow of €14.57 million compared to a negative free cash flow in 2023. This indicates better cash generation from operations. The operating cash flow to net income ratio of 10.32 is strong, reflecting effective cash conversion from income. However, the past volatility in cash flows warrants careful monitoring.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	67.00M	28.57M	20.20M	80.07M	765.00K
Gross Profit	66.70M	28.22M	19.95M	79.91M	563.00K
EBITDA	8.35M	-22.24M	-25.80M	34.91M	-73.03M
Net Income	1.51M	-28.89M	-23.72M	67.26M	-101.22M
Balance Sheet
Total Assets	151.42M	173.87M	215.54M	281.72M	198.61M
Cash, Cash Equivalents and Short-Term Investments	81.79M	77.79M	140.55M	258.76M	171.03M
Total Debt	62.13M	70.18M	75.28M	74.23M	185.69M
Total Liabilities	82.20M	105.92M	121.01M	162.62M	214.78M
Stockholders Equity	69.22M	67.95M	94.53M	119.10M	-16.16M
Cash Flow
Free Cash Flow	14.22M	-57.92M	-72.64M	99.38M	-97.27M
Operating Cash Flow	15.20M	-55.43M	-72.64M	99.92M	-96.37M
Investing Cash Flow	-1.04M	2.23M	-46.27M	-3.38M	-966.00K
Financing Cash Flow	-10.57M	-5.10M	-3.79M	-8.92M	-8.26M

Genfit SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNFT, the sentiment is Negative. The current price of 3.96 is below the 20-day moving average (MA) of 4.13, below the 50-day MA of 4.06, and above the 200-day MA of 3.92, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 43.06 is Neutral, neither overbought nor oversold. The STOCH value of 38.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GNFT.

Genfit SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FDMT	58 Neutral	$490.84M	―	-38.87%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GNFT	48 Neutral	$206.09M	-4.79	-51.06%	―	-44.94%	-274.42%
ENGN	42 Neutral	$324.56M	―	-43.95%	―	―	―
OMER	40 Underperform	$475.71M	―	―	―	―	10.15%
RAPT	39 Underperform	$708.83M	-2.01	-77.83%	―	―	43.16%

Genfit SA Corporate Events

GENFIT to Delist from Nasdaq, Focuses on Euronext Paris

On October 30, 2025, GENFIT announced its decision to voluntarily delist its American Depositary Shares (ADSs) from the Nasdaq Global Select Market, effective before November 20, 2025. This strategic move aims to simplify the company’s corporate structure and enhance operational efficiency, while maintaining its primary listing on Euronext Paris. The delisting will not affect GENFIT’s commitment to high standards of corporate governance and transparency, nor will it impact its accounting standards. The company will continue to comply with French and European financial regulations, and the delisting process involves filing necessary forms with the U.S. Securities and Exchange Commission.

GENFIT Showcases ACLF Pipeline Advances at AASLD Liver Meeting 2025

On October 28, 2025, GENFIT announced its participation in the upcoming AASLD The Liver Meeting® 2025, where it will present new data on its ACLF pipeline, including the lead program G1090N, and other programs like SRT-015 and CLM-022. The company will also present real-world evidence and biomarker insights in cirrhosis. Ipsen, a partner of GENFIT, will present data on Iqirvo® in rare cholestatic liver diseases, highlighting its potential to address disease progression and symptom burden. These presentations underscore GENFIT’s commitment to advancing treatments for liver diseases and enhancing its industry positioning.

GENFIT S.A. Releases Half-Year Financial Report for 2025

On September 22, 2025, GENFIT S.A. released its Half-Year Business and Financial Report for the period ending June 30, 2025. The report details the company’s ongoing R&D programs, including developments in their ACLF franchise and other serious diseases. The report also highlights the company’s strategic outlook and financial performance, providing insights into GENFIT’s industry positioning and potential implications for stakeholders.

GENFIT’s Strategic Shift and Financial Update for H1 2025

On September 22, 2025, GENFIT announced its first-half 2025 financial results, highlighting a cash position of €107.5 million as of June 30, 2025, and significant revenue from milestone payments related to its drug Iqirvo® (elafibranor) in Europe. The company decided to discontinue its VS-01 program for ACLF due to safety concerns but remains committed to other ACLF-related programs and continues to explore new therapeutic avenues. The withdrawal of a key competitor from the U.S. market is expected to benefit Iqirvo® sales. GENFIT’s strategic moves, including the acquisition of full rights for GNS561 and a royalty financing agreement, have extended its cash runway beyond 2028, providing financial stability and opportunities for further development initiatives.

GENFIT Discontinues VS-01 Program in ACLF to Focus on UCD

On September 19, 2025, GENFIT announced the discontinuation of its VS-01 program for Acute-on-Chronic Liver Failure (ACLF) due to safety concerns, specifically a serious adverse event in the UNVEIL-IT® clinical trial. The company will refocus VS-01 development on Urea Cycle Disorder (UCD), a condition with significant unmet medical needs. This strategic shift is expected to reduce operating expenses and extend GENFIT’s cash runway beyond 2028, while allowing the company to explore new approaches in ACLF care. GENFIT remains committed to its other ACLF programs and aims to deliver positive results from its pipeline, including safety data for G1090N by year-end.